Physician profile
James L Case
NPI 1992708853
$2,510.13
in general payments reported to CMS, 2019-2025
21 companies · $371 in 2025
The $371 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.67 · 2021: $129 · 2022: $159 · 2023: $959 · 2024: $818 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,147.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $648.03 | 2023-2025 | Inspire |
| Abbvie INC. | $467.96 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Acadia Pharmaceuticals INC | $211.03 | 2023-2025 | Nuplazid |
| Argenx US, INC. | $181.19 | 2022-2025 | Vyvgart |
| Itamar Medical INC | $135.09 | 2024 | Watchpatone |
| Lilly USA, LLC | $117.78 | 2019-2024 | Emgality, Jardiance, Reyvow |
| Amgen INC. | $96.77 | 2022-2024 | Aimovig |
| Lundbeck LLC | $88.75 | 2023-2025 | Vyepti |
| Ge Healthcare | $86.11 | 2022-2024 | |
| Allergan, INC. | $77.00 | 2019-2021 | |
| Sk Life Science, INC. | $73.51 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $66.62 | 2022-2025 | Ultomiris |
| Csl Behring | $47.77 | 2023 | Hizentra |
| Pfizer INC. | $46.73 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $37.00 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $34.76 | 2024 | Valtoco |
| Springworks Therapeutics, INC. | $22.41 | 2025 | Gomekli |
| Amneal Pharmaceuticals LLC | $19.80 | 2023 | Rytary |
| Merz Pharmaceuticals, LLC | $19.39 | 2025 | Xeomin |
| Biogen, INC. | $16.51 | 2021 | |
| Abbott Laboratories | $15.92 | 2024 | Infinity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.